What if you invested $1000 in VRTX on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Vertex Pharmaceuticals Incorporated has delivered an average annual return of 19.5%. The stock peaked in 2017 with a massive +100.1% gain, while investors faced a downturn in 2016 (-40.1%). Overall, the stock finished in the green 14 times out of 20 years.
Avg Return
+19.5%
Win Rate
70%
14W - 6L
Best
+100.1%
2017
Worst
-40.1%
2016
Performance Consistency
About Vertex Pharmaceuticals Incorporated
Visit Website ↗Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. It is a leader in treating cystic fibrosis (CF).
Key Business Segments
Pharmaceutical Products
CF treatments (Trikafta) and pipeline in sickle cell, pain, and diabetes.
Key Innovations
- ✓CFTR modulators for cystic fibrosis
- ✓CASGEVY (CRISPR-based gene editing therapy)
Historical Milestones
Founded by Joshua Boger.
FDA approval of Kalydeco (first CF drug).